AMG 337 + mFOLFOX6

AMG 337 + mFOLFOX6 is an investigational combination therapy evaluated for the first-line treatment of MET-amplified or MET-high advanced gastric, esophageal, and gastroesophageal junction (GEJ) adenocarcinomas. AMG 337 is a highly selective, oral, ATP-competitive small-molecule inhibitor of the MET (c-Met) receptor tyrosine kinase, which blocks signaling pathways involved in tumor cell proliferation, invasion, and survival. mFOLFOX6 is a standard chemotherapy regimen comprising oxaliplatin (a platinum-based antineoplastic that induces DNA cross-linking), leucovorin calcium (a folate analog that stabilizes the binding of fluorouracil to its target), and fluorouracil (a pyrimidine analog that inhibits thymidylate synthase). The combination was studied by the Eastern Cooperative Oncology Group (ECOG) in a Phase I/II trial to determine if adding a targeted MET inhibitor to standard cytotoxic chemotherapy could improve outcomes in patients with HER2-negative, MET-high tumors. However, the clinical development of AMG 337 was ultimately terminated by Amgen.

Other names

AMG 337 + oxaliplatin + leucovorin calcium + fluorouracil